CFT1946 free base · Synonyms: CFT-1946 · CFT 1946

CFT1946 is an orally active and selective target ligand.

For research use only. Not for human or veterinary use.

Target PROTACs Raf

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

CFT1946 structure

CAS No.: 2882165-79-7

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
25 mg	USD 798.00	BP-02369-25mg	In stock	Get quote
50 mg	USD 1,398.00	BP-02369-50mg	In stock	Get quote
100 mg	USD 2,280.00	BP-02369-100mg	In stock	Get quote
250 mg	Inquire	BP-02369-250mg	In stock	Inquire

Custom Size Bulk Inquiry

Description

CFT1946 is an orally active and selective target ligand for BRAF kinase. CFT1946 is a degrader of mutant BRAFV600E, G469A, G466V and p61-BRAFV600E. CFT1946 can be used in tumor research.

Biological activity

Tagarafdeg (CFT1946) (100 nM; 24 h) causes BRAFV600E degradation and inhibits MAPK Signaling with pERK loss in BRAFV600E cells but not in WT-BRAF cells Tagarafdeg (CFT1946) (0.3-10 mg/kg; PO; BID; 20 days) induces tumor regression in the BRAFV600E A375 xenograft mouse model with 10 mg/kg

Identifiers

SMILES: CN1C(C(C(N(CCC2=O)C(N2)=O)=N1)=C3)=CC(N(CC4)CCC4(O)CC(N5CCC6(C[C@@H](N(C=NC7=CC=C8OC(C(F)=CC=C9N[S](N(C)CC)(=O)=O)=C9C#N)C(C7=C8)=O)CO6)CC5)=O)=C3F
InChIKey: OCDRMYDQTIPVOI-HHHXNRCGSA-N

Specifications

MW (average): 958.0010
Formula: C₄₅H₄₉F₂N₁₁O₉S
CAS No.: 2882165-79-7
Physical state: Solid
Color: Off-white to light yellow
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO

In vitro: DMSO : 100 mg/mL

Documents

References

[1]. Yanke Liang. The Discovery and Characterization of CFT1946: A Potent, Selective, and Orally Bioavailable Degrader of Mutant BRAF for the Treatment of BRAF-driven Cancers. ANNUAL MEETING, American Association for Cancer Research, 2023.

[2]. Rudolph J, et al. Contemporary design of small-molecule kinase modulators: orthosteric, allosteric and induced-proximity strategies. Nature reviews. Drug discovery. 2026 Aug;25(8):595-618.

[3]. Kreger B T, et al. CFT1946 Is an Orally Available Brain‑Penetrant BRAFV600‑Mutant Degrader That Overcomes BRAF Inhibitor Resistance. Cancer Research, 2026, 86(2):438‑452.

Same target

Search PROTACs

Same research area

Search Cancer